QEP Resources, Inc. (QEP) continued its upward trend with the stock climbing 0.95% or $0.16 to close the day at $16.93 on lower than average trading volume of 2.96M shares, compared to its three month average trading volume of 3.07M. The Denver Colorado 80265 based company has been outperforming the oil & gas pipelines companies by 5.548% for last three months and its recent gains have offset losses to -8.04% YTD, versus the oil & gas pipelines industry which is up 4.76% for the same period. The RSI of 36.67 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.
QEP Resources, Inc., through its subsidiaries, operates as a natural gas and crude oil exploration and production company in the United States. The company conducts exploration and production activities in the Pinedale Anticline in western Wyoming; the Williston Basin in North Dakota; the Uinta Basin in eastern Utah; the Permian Basin in western Texas; the Haynesville/Cotton Valley in northwestern Louisiana; and other proven properties in Wyoming, Utah, and Colorado. As of December 31, 2015, it had estimated proved reserves of 3,620.2 billion cubic feet of natural gas equivalents. The company sells its gas, oil, and natural gas liquids (NGL) to various customers, including gas-marketing firms, industrial users, local-distribution companies, crude oil refiners, and remarketers, as well as markets affiliate and third-party gas, oil, and NGL volumes. In addition, it operates a gas gathering system and an underground gas storage facility. QEP Resources, Inc. is headquartered in Denver, Colorado.
Uranium Energy Corp. (UEC) had a active trading with around 2.96M shares changing hands compared to its three month average trading volume of 2.06M. The stock traded between $1.67 and $1.76 before closing at the price of $1.7 with 2.41% change on the day. The Vancouver British Columbia V6E 2Y3 based company is currently trading 146.38% above its 52 week low of $0.69 and -6.59% below its 52 week high of $1.82. Both the RSI indicator and target price of 60.4 and $2.79 respectively, lead us to believe that it should be put on hold over the coming weeks.
Uranium Energy Corp. engages in the exploration, pre-extraction, extraction, and processing of uranium concentrates on projects located in the United States and the Republic of Paraguay. As of July 31, 2016, it had mineral rights in uranium projects located in the states of Arizona, Colorado, New Mexico, Texas, and Wyoming, as well as in the Republic of Paraguay. The company was formerly known as Carlin Gold Inc. and changed its name to Uranium Energy Corp. in January 2005. Uranium Energy Corp. was incorporated in 2003 and is based in Corpus Christi, Texas.
Novavax, Inc. (NVAX) traded within a range of $1.29 to $1.33 after opening the day at $1.29. The company has seen its stock increase in value by 4.76% so far this year. The stock was up close to 0.76% on light volume in last trading session and closed at $1.32 per share. After the recent gain, the stock is currently holding -84.45% below its 52 week high of $8.49 and 13.79% above its 12-month low of $1.16. The shares are down by over -8.97% in the last three months, and the RSI indicator value of 45.93 is neither bullish nor bearish, tempting investors to stay on the sidelines.
Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, as well as pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.